• Strona główna
  • Wyniki wyszukiwania
  • MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1.

MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1.

Molecular and cellular biology (2014-09-10)
Sriganesh B Sharma, Chen-Chung Lin, Mark K Farrugia, Sarah L McLaughlin, Emily J Ellis, Kathleen M Brundage, Mohamad A Salkeni, J Michael Ruppert
ABSTRAKT

Despite the low prevalence of activating point mutation of RAS or RAF genes, the RAS-extracellular signal-regulated kinase (ERK) pathway is implicated in breast cancer pathogenesis. Indeed, in triple-negative breast cancer (TNBC), there is recurrent genetic alteration of pathway components. Using short hairpin RNA (shRNA) methods, we observed that the zinc finger transcription factor Krüppel-like factor 4 (KLF4) can promote RAS-ERK signaling in TNBC cells. Endogenous KLF4 bound to the promoter regions and promoted the expression of two microRNAs (miRs), miR-206 and miR-21 (i.e., miR-206/21). Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 and SPRED1. In TNBC cells, including cells with mutation of RAS, the suppression of either RASA1 or SPRED1 increased the levels of GTP-bound, wild-type RAS and activated ERK 1/2. Unlike the control cells, treatment of RASA1- or SPRED1-suppressed cells with anti-miR-206/21 had little or no impact on the level of activated ERK 1/2 or on cell proliferation and failed to suppress tumor initiation. These results identify RASA1 and SPRED1 mRNAs as latent RAS-ERK pathway suppressors that can be upregulated in tumor cells by anti-miR treatment. Consequently, KLF4-regulated miRs are important for the maintenance of RAS-ERK pathway activity in TNBC cells.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
L-Glutathione reduced, ≥98.0%
Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Sigma-Aldrich
L-Glutathione reduced, BioReagent, suitable for cell culture, ≥98.0%, powder
Sigma-Aldrich
Anti-HA antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Supelco
Glutathione, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone HA-7, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone HA-7, ascites fluid
Sigma-Aldrich
L-Glutathione reduced, BioXtra, ≥98.0%
Glutathione, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone 1B8, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone 4D4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone 1F7, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone 3C6, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-HA antibody produced in mouse, clone 3F6, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human MLXIP
Sigma-Aldrich
MISSION® esiRNA, targeting human MARCH8
Sigma-Aldrich
MISSION® esiRNA, targeting human MYLIP
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mlxip
Sigma-Aldrich
MISSION® esiRNA, targeting mouse March8

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.